Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 1

Research Article

Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 1

Demographic and clinical features, laboratory parameters, prognostic scores, and decompensation characteristics between the two groups.

VariablesUDCA-only group (N=14)UDCA+IS group (N=14)P value

Age at entry (years)60.0 (51.3, 61.3)48.0 (42.5, 53.5)0.024
Gender (F/M)13/112/2>0.999
TBIL, μmol/L29.0 (23.2, 41.1)38.9 (35.2, 127.1)0.035
ALT, IU/L66.5 (44.8, 127.0)112.0 (45.7, 174.5)0.401
AST, IU/L103.5 (78.5, 129.8)170.0 (91.0, 212.5)0.401
ALP, IU/L349.5 (257.8, 519.0)294.0 (196.5, 430.5)0.285
GGT, IU/L268.5 (157.0, 656.3)229.5 (51.8, 293.5)0.285
ALB, g/L37.6 (31.8, 39.9)32.3 (29.9, 35.5)0.031
GLB, g/L43.4 (37.4, 47.1)45.4 (35.3, 50.2)0.511
INR1.1 (1.0, 1.2)1.1 (1.0, 1.2)0.734
Cr, μmol/L57.3 (51.8, 66.3)53.5 (43.3, 61.3)0.137
ANA positive, N (%)13/1412/14>0.999
AMA positive, N (%)9/149/14>0.999
LKM positive, N (%)00-
LC-1 positive, N (%)00-
SLA positive, N (%)00-
Concurrent autoimmune diseases, N (%)4/146 /140.695
IgG (g/L)22.8 (20.2, 25.7)28.6 (19.7, 32.4)0.125
IgM (g/L)2.2 (1.3, 5.7)2.7 (2.4, 3.0)0.306
APRI score3.9 (2.2, 5.3)6.4 (3.9, 7.2)0.051
FIB-4 index6.6 (4.9, 8.7)11.7 (6.7, 18.9)0.075
Complications
Ascites12/1410/140.648
Variceal bleeding2/144/140.648
Prognostic scores
Child-Pugh score6.5 (6.0, 7.0)8.0 (6.0, 8.0)0.265

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; ALB, albumin; GLB, globulin; ANA, antinuclear antibody; AMA, anti-mitochondrial antibody; LKM, liver–kidney microsomal antibody; LC-1, antibody against liver cytosol type 1 antigen; SLA, soluble liver antigen/liver pancreas antibody; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis 4 index.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.